KH 176

Drug Profile

KH 176

Alternative Names: KH176

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Khondrion
  • Class
  • Mechanism of Action Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - MELAS syndrome; Leigh disease; Mitochondrial disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mitochondrial disorders
  • Preclinical Parkinson's disease

Most Recent Events

  • 06 Sep 2016 Phase-II clinical trials in Mitochondrial disorders in Netherlands (PO) (EudraCT2016-001696-79) (NCT02909400)
  • 10 Aug 2015 KH 176 receives Orphan Drug status for MELAS syndrome in European Union
  • 01 May 2015 Preclinical trials in Parkinson's disease in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top